Search

Your search keyword '"Cristian D. Valenzuela"' showing total 15 results
Start Over Author "Cristian D. Valenzuela" Publisher springer science and business media llc
15 results on '"Cristian D. Valenzuela"'

4. ASO Visual Abstract: Survival Outcomes of Optimally Treated Colorectal Metastases–The Importance of R0 Status in Surgical Treatment of Hepatic and Peritoneal Surface Disease

Author

Ian Solsky, Omeed Moaven, Cristian D. Valenzuela, Megan Lundy, John A. Stauffer, Nico R. Del Piccolo, Tanto Cheung, Carlos U. Corvera, Andrew D. Wisneski, Charles Cha, Nima Pourhabibi Zarandi, Justin Dourado, Gregory Russell, Edward A. Levine, Konstantinos I. Votanopoulos, and Perry Shen

Subjects
Oncology, Surgery
Published
2023

15. Effects of nintedanib on the microvascular architecture in a lung fibrosis model

Author

Yong Ook Kim, Detlef Schuppan, Cristian D. Valenzuela, Maximilian Ackermann, Steven J. Mentzer, Moritz A. Konerding, Detlef Stiller, Sebastian Kreuz, Willi L. Wagner, and Lutz Wollin

Subjects
0301 basic medicine, Cancer Research, Vital capacity, Pathology, medicine.medical_specialty, Indoles, Physiology, medicine.drug_class, Clinical Biochemistry, Neovascularization, Physiologic, Bleomycin, Article, Tyrosine-kinase inhibitor, 03 medical and health sciences, chemistry.chemical_compound, Idiopathic pulmonary fibrosis, Imaging, Three-Dimensional, 0302 clinical medicine, Pulmonary fibrosis, medicine, Animals, Intussusceptive angiogenesis, Cell Proliferation, medicine.diagnostic_test, business.industry, Pneumonia, X-Ray Microtomography, respiratory system, medicine.disease, Idiopathic Pulmonary Fibrosis, Respiratory Function Tests, Mice, Inbred C57BL, Pulmonary Alveoli, Disease Models, Animal, 030104 developmental biology, Bronchoalveolar lavage, chemistry, 030220 oncology & carcinogenesis, Microvessels, Nintedanib, Collagen, business
Abstract

Nintedanib, a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis, has anti-fibrotic, anti-inflammatory, and anti-angiogenic activity. We explored the impact of nintedanib on microvascular architecture in a pulmonary fibrosis model. Lung fibrosis was induced in C57Bl/6 mice by intratracheal bleomycin (0.5 mg/kg). Nintedanib was started after the onset of lung pathology (50 mg/kg twice daily, orally). Micro-computed tomography was performed via volumetric assessment. Static lung compliance and forced vital capacity were determined by invasive measurements. Mice were subjected to bronchoalveolar lavage and histologic analyses, or perfused with a casting resin. Microvascular corrosion casts were imaged by scanning electron microscopy and synchrotron radiation tomographic microscopy, and quantified morphometrically. Bleomycin administration resulted in a significant increase in higher-density areas in the lungs detected by micro-computed tomography, which was significantly attenuated by nintedanib. Nintedanib significantly reduced lung fibrosis and vascular proliferation, normalized the distorted microvascular architecture, and was associated with a trend toward improvement in lung function and inflammation. Nintedanib resulted in a prominent improvement in pulmonary microvascular architecture, which outperformed the effect of nintedanib on lung function and inflammation. These findings uncover a potential new mode of action of nintedanib that may contribute to its efficacy in idiopathic pulmonary fibrosis.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results